RGIE:一种与头部和部状细胞癌的放射治疗抵抗相关的基因选择方法
Qingzhe Meng1,2, Dunhui Liu3, Junhong Huang1
1Department of Oral and Maxillofacial Surgery, School of Stomatology, Fourth Military Medical University, Xi'an, China.
Current radiopharmaceuticals
|March 27, 2024
概括
研究人员使用RGIE算法识别了9个关键基因,这些基因与头部和部状细胞癌 (HNSCC-RR) 抗辐射疗法相关. 这一发现有助于开发针对HNSCC患者的向疗法.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 生物信息学是一种生物信息学.
背景情况:
- 头部和部状细胞癌 (HNSCC) 呈现出高恶性瘤和转移率.
- 放射治疗对于HNSCC治疗至关重要,改善生存率并减少复发.
- 鉴定与HNSCC放射治疗耐药性 (HNSCC-RR) 相关的基因对于新的治疗点至关重要.
研究的目的:
- 开发一种有效的算法来识别HNSCC-RR基因.
- 解决从大型基因组数据集中选择相关基因的挑战.
- 为了找到HNSCC放射治疗反应的潜在生物标志物.
主要方法:
- 开发了一种新的基因选择算法,RGIE.
- RGIE集成了ReliefF用于特征选择,GENIE3用于基因网络推断和特征消除.
- 这种方法分析基因调节关系,以确定HNSCC-RR的歧视性特征.
主要成果:
- 该RGIE算法发现了9个特定的基因 (SPAG1,FIGN,NUBPL,CHMP5,TCF7L2,COQ10B,BSDC1,ZFPM1,GRPEL1) 与HNSCC-RR.R.相关.
- 这些基因实现了高性能指标:精度 (0.9730),精度 (0.9679),回忆 (0.9767),和AUC (0.9885).
- 定量逆转录PCR (qRT-PCR) 验证了这些9个基因在HNSCC细胞系中的差异性表达.
结论:
- RGIE算法对于选与HNSCC放射治疗耐药性相关的基因是有效的.
- 这些已识别的基因可能成为HNSCC.的潜在治疗点.
- 这种方法有可能指导HNSCC患者的临床治疗策略.
更多相关视频
08:32Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
Published on: May 23, 2025
146
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.2K
相关概念视频
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
00:59Gene Therapy
25.4K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.4K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K